CliffBio
small molecule

EXEMESTANE

EXEMESTANE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameEXEMESTANE
Active ingredientEXEMESTANE
Strength25MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2018
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

EXEMESTANE patent cliff — loss of exclusivity — | CliffBio